|
Advertisement |
|
|
||
 |
|
|||||
|
|||||
|
 |
||||||
|
||||||
|
||||||
|
JCO Early Release, published online ahead of print Aug 13 2007
Received November 22, 2006 High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Results of a Phase III Intergroup Trial of the AGO-Ovar/AIO and EBMT
From the Department of Obstetrics and Gynecology, Städtisches Klinikum Frankfurt a.M.-Höchst; Department of Hematology and Oncology, Klinikum Nürnberg; Department of Hematology and Oncology, Dr Horst Schmidt Kliniken Wiesbaden; Department of Obstetrics and Gynecology, University Hospital Essen, Germany; Department of Hematology and Oncology, University Hospital Grosshadern, München; Wissenschaftlicher Service Pharma (WiSP), Langenfeld, Germany; Department of Hematology and Oncology, University Hospital Modena, Italy; European Group for Blood and Marrow Transplantation, University College Hospital; and the Department of Oncology, University College London, London, United Kingdom. * To whom correspondence should be addressed. E-mail: vmoebus{at}skfh.de
Purpose: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon. A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome. Patients and Methods: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support. HD melphalan was added to the final cycle. The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%. Results: Seventy-six percent of patients received all five cycles in the HD arm and the main toxicities were neuro-/ototoxicity, gastrointestinal toxicity, and infection and one death from hemorrhagic shock. After a median follow-up of 38 months, the progression-free survival was 20.5 months in the standard arm and 29.6 months in the HD arm (hazard ratio [HR], 0.84; 95% CI, 0.56 to 1.26; P, .40). Median overall survival (OS) was 62.8 months in the standard arm and 54.4 months in the HD arm (HR, 1.17; 95% CI, 0.71 to 1.94; P, .54). Conclusion: This is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer. We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
This article has been cited by other articles:
|
||||||||||||||||||||||||
|
|
|||||||||||
|
|||||||||||
|
|
Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|
